Inhibitory effect of carrimycin on biological activity of oral squamous cell carcinoma cells in vitro

doi:10.19438/j.cjoms.2020.04.004

Abstract

Abstract: PURPOSE: As a new macrolide antibiotic with independent intellectual property rights of China, carrimycin not only has good antibacterial effect on a variety of bacteria, but also has the function of regulating cell physiology and proliferation.The aim of this study was to investigate the anti-tumor effects of carrimycin on the biological activity of oral squamous cell carcinoma (OSCC) cells in vitro. METHODS: OSCC cells (HN6/HB96 cell lines) were treated with gradient concentration of carrimycin. Cell proliferation was detected using CCK-8 kit, based on which cell growth curve was drawn. Cell migration ability was analyzed by wound-healing assay. Cell clone formation ability was analyzed by clone formation assay. Cell cycle and apoptosis were analyzed by flow cytometry. SPSS18.0 software package was used for statistical analysis. RESULTS: Carrimycin concentration-dependently inhibited cellular proliferation of OSCC cells of HN6 and HB96 in vitro. With the increase of drug concentration, cell migration and clonal formation ability significantly decreased (P<0.05). The G1 phase ratio of OSCC cells treated with carrimycin significantly increased, while the S and G2/M phase ratio decreased, indicating that the cell cycle was arrested in G1 phase(P<0.001). The apoptosis rate of OSCC cells was significantly increased with the increase of drug concentration (P<0.01). CONCLUSIONS: The activity of OSCC cells can be effectively inhibited by carrimycin, which provides experimental evidence for the application of carrimycin in OSCC.

Key words: Carrimycin, Antibiotics, Oral squamous cell carcinoma

CLC Number:

R739.8

LIANG Si-yuan, ZHAO Tong-chao, ZHOU Zhi-hang, JU Wu-tong, LIU Ying, ZHANG Zhi-yuan, ZHONG Lai-ping. Inhibitory effect of carrimycin on biological activity of oral squamous cell carcinoma cells in vitro[J]. China Journal of Oral and Maxillofacial Surgery, 2020, 18(4): 308-313.

References

[1] Ferlay J, Soerjomataram I, Dikshit R, et al.Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5): E359-E386.
[2] Ferlay J, Shin HR, Bray F, et al.Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008[J]. Int J Cancer, 2010, 127(12): 2893-2917.
[3] Torre LA, Bray F, Siegel RL, et al.Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108.
[4] Shang GD, Dai JL, Wang YG.Construction and physiological studies on a stable bioengineered strain of Shengjimycin[J]. J Antibiot, 2001, 54(1): 66-73.
[5] Hanahan D, Weinberg RA.Hallmarks of cancer: the next generation[J]. Cell, 2011, 144(5): 646-674.
[6] Sasahira T, Kirita T. Hallmarks of cancer-related newly prognostic factors of oral squamous cell carcinoma [J]. Int J Mol Sci, 2018, 19(8): piiE2413.
[7] Pistritto G, Trisciuoglio D, Ceci C, et al.Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies[J]. Aging, 2016, 8(4): 603-619.
[8] Foster KG, Fingar DC.Mammalian target of Rapamycin (mTOR): conducting the cellular signaling symphony[J]. J Biol Chem, 2010, 285(19): 14071-14077.
[9] Edelman MJ, Shvartsbeyn M.Epothilones in development for non-small-cell lung cancer: novel anti-tubulin agents with the potential to overcome taxane resistance[J]. Clin Lung Cancer, 2012, 13(3): 171-180.
[10] Demain AL, Vaishnav P.Natural products for cancer chemotherapy[J]. Microb Biotechnol, 2011, 4(6): 687-699.
[11] Eloy JO, Petrilli R, Chesca DL, et al.Anti-HER2 immunoliposomes for co-delivery of paclitaxel and rapamycin for breast cancer therapy[J]. Euro J Pharm Biopharm, 2017, 115: 159-167.
[12] Chen J, Stubbe J.Bleomycins: towards better therapeutics[J]. Nat Rev Cancer, 2005, 5(2): 102-112.
[13] Maximiliano C, Estefanía G, Ezequiel B, et al.Doxorubicin: nanotechnological overviews from bench to bedside[J]. Drug Discov Today, 2016, 22(2): 270-281.

[1]	REZIWANGULI·Yasen, MAIREPATI·Maiming, LI Chen-xi, GONG Zhong-cheng. Research progress in the role and mechanism of Porphyromonas gingivalis in promoting oral squamous cell carcinoma [J]. China Journal of Oral and Maxillofacial Surgery, 2023, 21(2): 186-190.
[2]	LAN Rong, RUAN Min, HAN Nan-nan, WANG Feng. Peri-implant squamous cell carcinoma appeared after implant-restoration in the left mandible: a case report [J]. China Journal of Oral and Maxillofacial Surgery, 2023, 21(2): 203-205.
[3]	LIU Heng, DUAN Xiao-feng. Research progress of ferritinophagy and related genes FTH1 and NCOA4 in oral squamous cell carcinoma [J]. China Journal of Oral and Maxillofacial Surgery, 2023, 21(1): 87-91.
[4]	JI Ping-ping, LI Li, WU Yi-fan, HOU Li-li. Effect of transcutaneous electrical acupoint stimulation on myelosuppression in patients with oral squamous cell carcinoma after induction chemotherapy [J]. China Journal of Oral and Maxillofacial Surgery, 2022, 20(5): 455-460.
[5]	XU Gang, SONG Qi-yi, JIANG Wei-dong, LIU Jing-xiu. Expression and clinical significance of aquaporin 3 in oral mucosal epithelial dysplasia and oral squamous cell carcinoma [J]. China Journal of Oral and Maxillofacial Surgery, 2022, 20(5): 478-482.
[6]	YANG Song, WANG Ning, ZHAO Shu-chao, LI Heng-yong, GE Sheng-you, ZHOU Kai, SONG Kai, SHANG Wei, FENG Yuan-yong. Expression and clinical significance of chemerin in oral squamous cell carcinoma patients combined with type 2 diabetes [J]. China Journal of Oral and Maxillofacial Surgery, 2022, 20(4): 390-395.
[7]	ZHANG Yi-yi, YANG Yue-yi, JU Wu-tong, ZHONG Lai-ping. Neoadjuvant immunotarget therapy in patients with locally advanced oral squamous cell carcinoma: report of 2 cases and literature review [J]. China Journal of Oral and Maxillofacial Surgery, 2022, 20(4): 413-416.
[8]	WEI Dong-liang, LI Zhi, JU Hou-yu, WU Yun-teng, GUO Wei, REN Guo-xin. Mechanism of EGFR-targeted drugs for pain relief in oral cancer [J]. China Journal of Oral and Maxillofacial Surgery, 2022, 20(3): 219-224.
[9]	SUN Da-wei, ZHANG Yun, ZHU Yong. Effect of shRNA interference Rce1gene expression on the radiosensitivity of oral squamous cell carcinoma cells [J]. China Journal of Oral and Maxillofacial Surgery, 2022, 20(2): 123-128.
[10]	NUERMANGULI·Yasen, DUOLIKUN·Wufuer, BAIERNA·Wushuoer, YAN Guang-peng. The relationship between serum IL-6, IL-17, TNF-α, IFN-γ levels, clinical characteristics of60patients with oral squamous cell carcinoma [J]. China Journal of Oral and Maxillofacial Surgery, 2022, 20(2): 141-145.
[11]	QU Chu-xiang, SUN Shu-yang, ZHANG Zhi-yuan. Understanding oral cancer invasion from the perspective of genetic heterogeneity [J]. China Journal of Oral and Maxillofacial Surgery, 2022, 20(2): 193-197.
[12]	WANG Yu-xin, WANG Zhi-yong, WANG Yong-gong, WANG Hui-ming, WANG Li-zhen, TIAN Hao, YE Jin-hai, FU Kun, RUAN Min, SUN Chang-fu, SUN Guo-wen, LIU Fa-yu, XU Bi-yun, HOU Jun, LIU Bing, LIU Liang, CHEN Yong-feng, CHEN Zhan-wei, XIAO Can, LI Si-yi, LI Zhi-yong, LI Yong, LI Nan, ZHANG Chen-ping, ZHANG Dong-sheng, ZHANG Sheng, ZHANG Kai, YANG Xi, HE Wei, SU Tong, JI Tong, LIN Li-song, LUO Rui-hua, ZHAO Zhi-li, HU Qin-gang, TANG Zhan-gui, XU Wei-jia, HUANG Zhi-quan, HUANG Xiao-feng, LIANG Yu-jie, HAN Zheng-xue, HAN Wei, JIANG Can-hua, YU Jian-jun, CAI Zhi-gang, LIAO Gui-qing, LIAO Sheng-kai, CAI Hui-ming, WEI Jian-hua. Chinese expert consensus statement on the application of of indocyanine green(ICG) fluorescence imaging in the treatment of oral squamous cell carcinoma [J]. China Journal of Oral and Maxillofacial Surgery, 2022, 20(1): 1-6.
[13]	LI Xing, XU Fei-hu, YANG Yun-bo, HAN Nan-nan, RUAN Min. Clinicopathological characteristics and prognostic analysis of oral squamous cell carcinoma with parotid lymph node metastasis [J]. China Journal of Oral and Maxillofacial Surgery, 2022, 20(1): 28-31.
[14]	YANG Yun-bo, WANG Yu-pu, LI Hang, HAN Nan-nan, YAN Ming, RUAN Min. Expression and clinical significance of cystatin A in oral squamous cell carcinoma [J]. China Journal of Oral and Maxillofacial Surgery, 2021, 19(6): 494-499.
[15]	HUANG Jin-yun, ZHANG Xin-yi, JU Hou-yu, JI Hong-hai, REN Guo-xin. Correlation between oral microbial homeostasis and cisplatin sensitivity in patients with oral squamous cell carcinoma [J]. China Journal of Oral and Maxillofacial Surgery, 2021, 19(6): 500-505.